Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human Phase I Dose Escalation Study Assessing Safety, Tolerability and Preliminary Efficacy of Immunomodulatory Nanoparticles

NCT04751786 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT04751786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04751786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human Phase I Dose Escalation Study Assessing Safety, Tolerability and Preliminary Efficacy of Immunomodulatory Nanoparticles
Lead sponsor
Radboud University Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 11, 2021
Completion date
December 31, 2026
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor